10-K: Immunovant Advances Best-in-Class FcRn Inhibitor IMVT-1402 with Multiple Registrational Trials Initiated and Strong Batoclimab Data Reported in Autoimmune Diseases

Immunovant, a clinical-stage immunology company, reported significant progress in its pipeline, initiating multiple registrational trials for its potentially best-in-class FcRn inhibitor IMVT-1402 across several autoimmune indications, while also announcing positive Phase 3 results for batoclimab in Myasthenia Gravis.

Summary

• Immunovant is a clinical-stage immunology company focused on developing IMVT-1402, a potentially best-in-class FcRn inhibitor, for autoimmune diseases driven by high levels of pathogenic IgG antibodies.
• In a Phase 1 clinical trial, IMVT-1402 demonstrated deep, dose-dependent IgG reductions, with the 600 mg dose expected to reach approximately 80% IgG reductions, and notably showed no or minimal reductions in albumin and no or minimal increases in LDL cholesterol levels, which are off-target effects observed in some other anti-FcRn antibodies, including batoclimab.
• The company has initiated potentially registrational trials for IMVT-1402 in Graves disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), and chronic inflammatory demyelinating polyneuropathy (CIDP), along with a proof-of-concept trial in cutaneous lupus erythematosus (CLE).
• Immunovant plans to initiate a second potentially registrational trial for IMVT-1402 in GD and a potentially registrational trial in Sjogren's disease (SjD) in the summer of 2025.
• Top-line results from the Phase 3 study of batoclimab in MG, announced in March 2025, met its primary endpoint, showing a 5.6 point mean improvement in MG-ADL score for the 680 mg dose and a 93% MG-ADL response rate in AChR+ patients, with 75% of patients maintaining Minimal Symptom Expression (MSE) for at least 6 weeks.
• Initial results from Period 1 of the Phase 2b study of batoclimab in CIDP, also announced in March 2025, demonstrated a mean improvement in the aINCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in patients achieving an IgG lowering of 70% or greater.
• For the fiscal year ended March 31, 2025, the company reported a net loss of $413.8 million, an increase from $259.3 million in the prior fiscal year, and had an accumulated deficit of $1,239.5 million.
• As of March 31, 2025, Immunovant held $714.0 million in cash and cash equivalents, and expects these funds to be sufficient to cover operating expenses and capital expenditure requirements for announced indications through the GD readout expected in 2027.
• The company completed a private placement in January 2025, issuing 22,500,000 shares of common stock at $20.00 per share, raising approximately $450.0 million in gross proceeds.

Sentiment

Score: 8

Explanation: The company reported very strong clinical data for both batoclimab and IMVT-1402, positioning IMVT-1402 as a potential best-in-class therapy with a differentiated safety profile. The aggressive advancement of multiple registrational trials for IMVT-1402 across several indications demonstrates a strong commitment to bringing these therapies to market. While losses are increasing, this is typical for a clinical-stage biotech, and the recent capital raise provides a solid cash runway through key milestones. The 'best-in-class' potential and differentiated profile of IMVT-1402 in a large market with unmet needs suggest significant future commercial potential, outweighing the inherent risks of drug development and competition.

Positives

• IMVT-1402 demonstrates best-in-class potential with approximately 80% IgG reductions at the 600 mg dose, offering deeper reductions than competitors, and a favorable safety profile with no or minimal reductions in albumin and no or minimal increases in LDL cholesterol, unlike batoclimab.
• Successful initiation of multiple potentially registrational trials for IMVT-1402 in Graves disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy, indicating rapid pipeline advancement.
• Positive Phase 3 results for batoclimab in Myasthenia Gravis met the primary endpoint, setting a new benchmark with a 5.6 point mean improvement in MG-ADL score and a 93% response rate for the 680 mg dose, demonstrating strong efficacy and durability.
• Initial Phase 2b results for batoclimab in CIDP showed a meaningful 1.8-point improvement in aINCAT disability score, which is double the change observed from an approved competitor, and an 84% responder rate for patients with significant IgG reductions.
• Batoclimab's Phase 2 proof-of-concept trial in Graves disease demonstrated significant IgG reduction (77%) and a high response rate (76%), with 56% of subjects achieving an ATD-Free Response, supporting the potential of FcRn inhibition in this indication.
• The company has a strong cash position of $714.0 million as of March 31, 2025, which is expected to fund operations for announced indications through the Graves disease readout expected in 2027.
• Leveraging data and operational experience from batoclimab trials is expected to inform and accelerate the development programs for IMVT-1402.

Negatives

• The company incurred significant and increasing net losses, reaching $413.8 million for the fiscal year ended March 31, 2025, up from $259.3 million in the prior year, and has an accumulated deficit of $1,239.5 million.
• Immunovant has never generated any product revenue and expects to incur significant operating losses for the foreseeable future, with no certainty of achieving or maintaining profitability.
• Batoclimab, the company's first-generation anti-FcRn antibody, was associated with off-target effects, specifically elevated total cholesterol and LDL levels, which required a voluntary pause in dosing in earlier clinical trials.
• The company relies heavily on third parties for manufacturing, clinical trials, and other critical business activities, introducing risks related to quality control, production difficulties, and compliance.
• The market for autoimmune disease therapies is highly competitive, with several established pharmaceutical companies and other FcRn inhibitors already approved or in advanced clinical development, posing a challenge to market penetration and pricing.
• Roivant Sciences Ltd. (RSL) maintains significant control over the company, owning approximately 56.5% of the voting power of outstanding common stock, which may lead to conflicts of interest with minority shareholders.
• The development of product candidates is inherently uncertain, expensive, and time-consuming, with no guarantee of regulatory approval or successful commercialization.
• There is a risk that product candidates, as antibody proteins, could cause an immune response in patients, leading to harmful or neutralizing antibodies that could limit effectiveness or regulatory approval.
• The company's ability to use its U.S. net operating loss carryforwards and certain other U.S. tax attributes may be limited due to ownership changes.

Risks

• The business is dependent on the successful and timely development, regulatory approval, and commercialization of product candidates, which is uncertain.
• Clinical trials are very expensive, time-consuming, difficult to design and implement, and involve uncertain outcomes, with failures possible at any stage.
• Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or impossible by factors outside the company's control.
• The results of nonclinical studies and clinical trials may not support proposed claims for product candidates, or regulatory approval on a timely basis or at all, and earlier results may not be predictive of future trial results.
• Interim, top-line, or preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
• Product candidates may be associated with adverse events or cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause suspension/discontinuation of trials, or limit commercial viability.
• Roivant Sciences Ltd. owns a significant percentage of shares of common stock and may exert significant control over matters subject to stockholder approval.
• The business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics and pandemics.
• The business could be adversely affected by economic downturns, changes in inflation and interest rates, changes in international trade policies and tariffs, natural disasters, political crises, geopolitical events.
• The company expects to incur significant losses for the foreseeable future and may never achieve or maintain profitability.
• Reliance on third parties to conduct, supervise, and monitor clinical trials, and if those third parties perform unsatisfactorily or fail to comply with requirements, it may harm the business.
• The company does not have its own manufacturing capabilities and relies on third parties to produce clinical and commercial supplies, which may encounter difficulties in production or quality issues.
• The company has a limited operating history and has never generated any product revenue.
• Additional capital will be required to fund operations, and failure to obtain necessary financing may prevent completion of development and commercialization.
• Raising additional funds by issuing equity securities will cause dilution to existing stockholders; debt financings may involve restrictive covenants; lending and licensing arrangements may restrict operations or require relinquishing proprietary rights.
• Reliance on the license agreement with HanAll Biopharma Co., Ltd. for rights to core intellectual property relating to IMVT-1402 and batoclimab; any termination or loss of significant rights would adversely affect development or commercialization.
• Significant competition from other biotechnology and pharmaceutical companies targeting autoimmune disease indications; operating results will suffer if the company fails to compete effectively.
• International expansion of the business exposes it to business, legal, regulatory, political, operational, financial, and economic risks associated with conducting business outside of the U.S.
• The company and third parties with whom it works are subject to stringent and changing privacy, data protection, and information security laws; actual or perceived failure to comply could result in harm to reputation, investigations, fines, liability, or disruption of clinical trials.
• If securities or industry analysts do not publish research or reports about the business or publish negative reports, share price and trading volume could decline.
• Product candidates are antibody proteins that could cause an immune response in patients, resulting in the creation of harmful or neutralizing antibodies.
• Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
• If the company is not able to obtain required regulatory approvals, it will not be able to commercialize product candidates, and its ability to generate product revenue will be impaired.
• Adverse developments that occur during clinical trials or manufacturing conducted by third parties in other jurisdictions may affect the company's ability to obtain regulatory approval or commercialize product candidates.
• Even if regulatory approval is obtained, the product may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community.
• The company may expend limited resources to pursue particular indications and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success.
• If the company is unable to establish sales, marketing, and distribution capabilities, either on its own or in collaboration with third parties, it may not be successful in commercializing its product candidates.
• The company may be unable to obtain or maintain orphan drug designation for IMVT-1402 or other product candidates.
• Additional time may be required to obtain marketing authorizations for pre-filled syringe or autoinjector presentations of product candidates due to regulation as combination products.
• Even if regulatory approval is obtained, the company will still face extensive ongoing quality and regulatory compliance requirements, and its product may face future development and quality or regulatory compliance difficulties.
• Current and future relationships with investigators, health care professionals, consultants, third-party payors, and customers are subject to applicable healthcare regulatory laws, which could expose the company to penalties.
• Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact the business in unpredictable ways.
• Coverage and adequate reimbursement may not be available for product candidates, which could make it difficult to sell them profitably.
• Disruptions at the FDA and other government authorities caused by funding shortages or global health concerns could hinder their ability to review and approve products.
• The company's product candidates for which it intends to seek approval as a biological product may face competition sooner than anticipated due to biosimilar pathways.
• The validity, scope, and enforceability of any patents that cover a biologic can be challenged by third parties.
• If the company is unable to obtain and maintain patent protection for product candidates or if the scope of protection is not sufficiently broad, it may not be able to compete effectively.
• Patent terms may be inadequate to protect the competitive position on product candidates for an adequate amount of time.
• The company does not have rights to protect intellectual property in certain territories and may be unable to adequately protect its rights.
• If the company fails to comply with obligations under any license, collaboration, or other agreements, it may be required to pay damages and could lose intellectual property rights.
• Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements.
• The company may not be successful in obtaining necessary intellectual property rights to future products through acquisitions and in-licenses.
• The company may need to license intellectual property from third parties, and such licenses may not be available or on commercially reasonable terms.
• Third-party claims or litigation alleging infringement of patents or other proprietary rights may delay or prevent the development and commercialization of product candidates.
• The company may not identify relevant third-party patents or may incorrectly interpret their relevance, scope, or expiration.
• If the company fails to identify or correctly interpret relevant patents to which it does not have a license, it may be subject to infringement claims.
• The company may become involved in lawsuits to protect or enforce its patents or other intellectual property rights, which could be expensive, time-consuming, and unsuccessful.
• The company may not be in a position to enforce its intellectual property rights against third parties due to expense and uncertainty of litigation.
• Changes in U.S. patent law or the patent law of other countries could diminish the value of patents.
• If the company is unable to protect the confidentiality of its trade secrets and other proprietary information, its business and competitive position could be harmed.
• The company may be subject to claims that its licensors, employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of former employers or other third parties.
• The company may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property.
• Any trademarks and trade names obtained may be infringed or successfully challenged, resulting in harm to the business.
• Intellectual property rights do not necessarily address all potential threats to the company's competitive advantage.
• The market price of shares of common stock has been and is likely to be highly volatile.
• The company has been and could be subject to securities litigation, which is expensive and could divert management attention.
• The company is a controlled company within the meaning of Nasdaq listing rules and qualifies for exemptions from certain corporate governance requirements.
• Because the company does not anticipate paying any cash dividends, capital appreciation, if any, would be the sole source of gain for investors.
• The company will continue to incur increased costs as a result of operating as a public company, and management will devote substantial time to compliance.
• Failure to manage the risks associated with international tax changes or misinterpretation of laws could result in costly audits, interest, penalties, and reputational damage.
• The intended tax effects of the corporate structure and intercompany arrangements depend on the application of tax laws of various jurisdictions and how the business operates.
• The company may become subject to unanticipated tax liabilities and higher effective tax rates.
• Anti-takeover provisions in charter documents and under Delaware law could make an acquisition more difficult.
• The Certificate of Incorporation designates specific exclusive forums for substantially all disputes, restricting stockholders' ability to choose judicial forums.

Future Outlook

Immunovant expects to incur significant and increasing operating losses and negative cash flows for the foreseeable future as it continues to fund its clinical development programs, including multiple registrational trials for IMVT-1402 and increased manufacturing activities. The company anticipates its existing cash and cash equivalents of $714.0 million as of March 31, 2025, will be sufficient to fund operating expenses and capital expenditure requirements for announced indications through the Graves disease readout expected in 2027. Future funding requirements will depend on the timing and success of clinical trials, regulatory approvals, and commercialization efforts, with plans to assess new indications for IMVT-1402 after executing the initial six priority indications.

Management Comments

• "Immunovant is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases."
• "We believe that FcRn inhibition has broad therapeutic and commercial potential to address IgG-mediated autoimmune diseases in several therapeutic areas..."
• "We expect to be able to reach approximately 80% IgG reductions with continued weekly dosing of 600 mg of IMVT-1402, offering deeper IgG reductions than observed with other competitor anti-FcRn programs."
• "We believe IMVT-1402s profile has the potential to offer best-in-class efficacy, in addition to its potentially favorable safety profile and convenient administration with a simple self-administered auto-injector expected at launch."
• "As previously disclosed, we will make a final decision about future development and regulatory submissions for batoclimab in the future based on the aggregate information available at the time."
• "Our primary focus is to execute these six indications first, with plans to assess new indications in the future."
• "We believe our Phase 3 batoclimab data demonstrates the meaningful potential efficacy benefit in MG with deeper IgG suppression than is available with current treatments, deeper disease control and more durable clinical responses."
• "Further, IMVT-1402s improved tolerability profile positions it to demonstrate a potentially superior therapeutic benefit even versus batoclimab."
• "We believe our Phase 2b batoclimab data demonstrates the meaningful potential efficacy benefit in CIDP with deeper IgG suppression than is available with current treatments."
• "The combined results of the batoclimab 340 mg and 680 mg dose arms achieved a best-in-class mean change from baseline in aINCAT score at week 12 of 1.8, double the change observed from the approved competitor."
• "We currently expect our existing cash and cash equivalents as of March 31, 2025 of $714.0 million will be sufficient to fund our operating expenses and capital expenditure requirements for announced indications to date through our GD readout expected in 2027."

Industry Context

The company operates in the highly competitive biopharmaceutical industry, specifically targeting autoimmune diseases with FcRn inhibitors. The market for anti-FcRn treatments is estimated to benefit over four million patients in the U.S. and Europe across more than 20 indications, with two approved indications already generating billions in sales. Key competitors in the FcRn inhibitor space include Argenx SE (efgartigimod), Johnson & Johnson (nipocalimab), and UCB (rozanolixizumab), all of whom have approved products or advanced clinical programs. Immunovant also faces competition from agents with different mechanisms of action across its target indications (MG, CIDP, GD, TED, RA, CLE, SjD) from companies like AstraZeneca, Amgen, Sanofi, Dianthus, Horizon Therapeutics, Viridian Therapeutics, Biogen, and others. The industry is also seeing significant M&A activity, such as Amgen's acquisition of Horizon Therapeutics and the merger of Alumic Inc. and ACELYRIN, INC., which could further concentrate resources among competitors.

Comparison to Industry Standards

• IMVT-1402's 600 mg dose is expected to achieve approximately 80% IgG reductions, which is stated to be deeper than observed with other competitor anti-FcRn programs.
• IMVT-1402 demonstrated no or minimal reductions in albumin and no or minimal increases in LDL cholesterol levels in Phase 1, which are off-target effects observed in some other anti-FcRn antibodies, including batoclimab, positioning it with a potentially more favorable safety profile.
• Batoclimab's 680 mg dose in the Phase 3 MG trial set a 'new benchmark for magnitude of benefit' with a 5.6 point mean improvement in MG-ADL, and its 340 mg arm was 'in line with other FcRn competitors approved or in development for MG,' while the 680 mg arm had 'the greatest absolute MG-ADL reduction observed in a global Phase 3 trial.'
• Batoclimab's initial Phase 2b CIDP results showed a 1.8-point improvement in aINCAT disability score, which is 'double the change observed from the approved competitor.'
• The company believes IMVT-1402's profile, including its convenient self-administered auto-injector, offers advantages over currently available treatments and approved FcRn inhibitors, which 'can leave patients with burdensome administration requirements, significant side effects or long wait times to see treatment effect.'

Management Changes

Corporate Governance

Legal Proceedings

• As of March 31, 2025, the company was not party to any material legal proceedings and no contingent liabilities were recorded.
• A securities class action complaint filed in February 2021 against the company, certain officers, and a board member was concluded in April 2024, with the court entering judgment in favor of the defendants, and no appeal was filed.

Related Party Transactions

• Roivant Sciences Ltd. (RSL) is the controlling stockholder, beneficially owning approximately 56.5% of the voting power of the company's outstanding common stock as of May 23, 2025.
• The company has Services Agreements with Roivant Sciences Inc. (RSI) and Roivant Sciences GmbH (RSG), wholly-owned subsidiaries of RSL, for development, administrative, and financial activities, incurring $0.8 million, $0.6 million, and $0.4 million in expenses for the years ended March 31, 2025, 2024, and 2023, respectively.
• A Cooperation Agreement with RSL obligates the company to provide periodic financial statements and other information to RSL and comply with specified financial reporting requirements.
• RSI subleased two floors of office space to the company, with the agreements expiring in February and April 2024, resulting in de minimis rent expense in FY2025.
• RSL participated in the company's equity offerings, including purchasing 16,845,010 shares in the January 2025 private placement, 4,473,684 shares in the October 2023 private placement, and 1,526,316 shares in the October 2023 underwritten public offering, and 416,667 shares in the October 2022 underwritten offering.

Stakeholder Impact

• Shareholders: Potential for significant value creation from successful clinical development and commercialization of IMVT-1402, but also face risks of dilution from future capital raises, stock price volatility, and RSL's controlling ownership.
• Patients: Potential for new, effective, and more convenient treatment options for various autoimmune diseases, particularly with IMVT-1402's differentiated safety profile and self-administered autoinjector.
• Employees: Expected growth in headcount, particularly in clinical development, quality, regulatory affairs, and commercial functions, offering career opportunities, but also subject to intense competition for talent.
• Suppliers and Contract Research Organizations (CROs): Continued reliance on third-party manufacturers and CROs for drug substance, drug product, and clinical trial execution, indicating ongoing business opportunities for these partners.
• Creditors: The company's increasing net losses and reliance on future capital raises for funding operations present a risk, though the current cash position provides a runway through key milestones.

Next Steps

• Make a final decision about future development and regulatory submissions for batoclimab based on aggregate information.
• Assess new indications for IMVT-1402 in the future, after executing the initial six priority indications.
• Initiate a second potentially registrational trial evaluating IMVT-1402 in Graves disease in the summer of 2025.
• Initiate a potentially registrational trial evaluating IMVT-1402 in Sjogren's disease in the summer of 2025.
• Report six-month remission data for batoclimab in Graves disease in the summer of 2025.
• Report Phase 3 TED data for batoclimab in the second half of calendar year 2025.
• Report initial results from Period 1 open label portion of the IMVT-1402 D2T RA trial in 2026.
• Report top-line results from the IMVT-1402 CLE trial in 2026.
• Report top-line results from the IMVT-1402 GD trial in 2027.
• Report top-line results from the IMVT-1402 MG trial in 2027.
• Report top-line results from the IMVT-1402 CIDP trial in 2028.
• Report top-line results from the IMVT-1402 SjD trial in 2028.
• Enter into commercial supply arrangements for IMVT-1402 prior to any potential approval.
• Build a small, targeted specialty sales organization in the U.S. if products are approved.
• Opportunistically seek strategic collaborations to maximize commercial opportunities for product candidates.
• Continue to incur significant and increasing operating losses and negative cash flows for the foreseeable future.
• Require additional capital to complete the development and potential commercialization of product candidates.

Key Dates

Recommendation

Keywords

Immunology, Autoimmune Diseases, FcRn Inhibitor, IMVT-1402, Batoclimab, Graves Disease, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Rheumatoid Arthritis, Cutaneous Lupus Erythematosus, Sjogren's Disease, Clinical Trials, Biopharmaceutical, Drug Development, SEC Filing, 10-K